QT Imaging Granted Renewal of NIH Sponsored Study for Early Identification of Response of Breast Cancer Patients to Neoadjuvant Chemotherapy
QT Imaging Holdings (NASDAQ:QTI) has received a third-year renewal of its five-year NIH/NCI research grant. The study, conducted in collaboration with Sunnybrook Health Sciences Centre and The University of Illinois, aims to develop an accurate breast imaging approach for early identification of breast cancer patients' response to neoadjuvant chemotherapy (NAC). The QTI Breast Acoustic CT™ System has been successfully used to collect high-resolution breast images with biomarkers sensitive to cancer. The next phase will incorporate AI/ML techniques to improve NAC efficacy estimates based on quantitative biomarkers from QTI scans and backscatter analysis.
QT Imaging Holdings (NASDAQ:QTI) ha ricevuto un rinnovo del terzo anno per il suo finanziamento di ricerca quinquennale NIH/NCI. Lo studio, condotto in collaborazione con il Sunnybrook Health Sciences Centre e l'Università dell'Illinois, mira a sviluppare un approccio di imaging mammario preciso per l'identificazione precoce della risposta dei pazienti con cancro al seno alla chemioterapia neoadiuvante (NAC). Il QTI Breast Acoustic CT™ System è stato utilizzato con successo per raccogliere immagini mammarie ad alta risoluzione con biomarcatori sensibili al cancro. La prossima fase incorporerà tecniche AI/ML per migliorare le stime di efficacia della NAC basate su biomarcatori quantitativi provenienti dagli scansioni QTI e dall'analisi del backscatter.
QT Imaging Holdings (NASDAQ:QTI) ha recibido la renovación del tercer año de su subvención de investigación de cinco años del NIH/NCI. El estudio, realizado en colaboración con el Sunnybrook Health Sciences Centre y la Universidad de Illinois, tiene como objetivo desarrollar un enfoque de imagen mamaria preciso para la identificación temprana de la respuesta de los pacientes con cáncer de mama a la quimioterapia neoadyuvante (NAC). El QTI Breast Acoustic CT™ System se ha utilizado con éxito para recopilar imágenes mamarias de alta resolución con biomarcadores sensibles al cáncer. La próxima fase incorporará técnicas de IA/ML para mejorar las estimaciones de eficacia de la NAC basadas en biomarcadores cuantitativos de escaneos QTI y análisis de retrodispersión.
QT Imaging Holdings (NASDAQ:QTI)는 5년 NIH/NCI 연구 보조금의 3년차 갱신을 받았습니다. 이 연구는 Sunnybrook Health Sciences Centre 및 일리노이 대학교와 협력하여 실시되며, 조기 유방암 환자의 신보조 화학요법(NAC) 반응을 정확하게 식별하기 위한 유방 이미지 방법 개발을 목표로 하고 있습니다. QTI Breast Acoustic CT™ System은 암에 민감한 바이오마커와 함께 고해상도의 유방 이미지를 수집하는 데 성공적으로 사용되었습니다. 다음 단계에서는 QTI 스캔과 후방산란 분석에서 얻은 정량적 바이오마커를 기반으로 NAC 효능 추정을 개선하기 위해 AI/ML 기술이 통합될 것입니다.
QT Imaging Holdings (NASDAQ:QTI) a reçu un renouvellement de troisième année de sa subvention de recherche de cinq ans du NIH/NCI. L'étude, menée en collaboration avec le Sunnybrook Health Sciences Centre et l'Université de l'Illinois, vise à développer une approche d'imagerie mammaire précise pour l'identification précoce de la réponse des patientes atteintes de cancer du sein à la chimiothérapie néoadjuvante (NAC). Le QTI Breast Acoustic CT™ System a été utilisé avec succès pour collecter des images mammaires haute résolution avec des biomarqueurs sensibles au cancer. La prochaine phase intégrera des techniques d'IA/ML pour améliorer les estimations d'efficacité de la NAC basées sur des biomarqueurs quantitatifs issus des scans QTI et de l'analyse des retours de diffusée.
QT Imaging Holdings (NASDAQ:QTI) hat eine Verlängerung des dritten Jahres seines fünfjährigen NIH/NCI-Forschungsgeldes erhalten. Die Studie, die in Zusammenarbeit mit dem Sunnybrook Health Sciences Centre und der Universität von Illinois durchgeführt wird, zielt darauf ab, einen genauen Ansatz für die Brustbildgebung zu entwickeln, um die frühe Identifizierung der Reaktion von Brustkrebspatienten auf die neoadjuvante Chemotherapie (NAC) zu ermöglichen. Das QTI Breast Acoustic CT™ System wurde erfolgreich verwendet, um hochauflösende Brustbilder mit krebsensitiven Biomarkern zu sammeln. Die nächste Phase wird AI/ML-Techniken integrieren, um die Effizienzschätzungen der NAC basierend auf quantitativen Biomarkern aus QTI-Scans und Rückstreuanalysen zu verbessern.
- Secured renewal of NIH/NCI research grant for the third year
- Successfully implemented and tested backscatter analysis method on in vivo breast imaging data
- Developing novel AI/ML applications with unique quantitative biomarkers
- None.
Insights
The grant renewal for QTI's breast cancer research represents incremental progress but has immediate financial impact. The collaboration with prestigious institutions like Sunnybrook and University of Illinois adds credibility to their research in neoadjuvant chemotherapy (NAC) response monitoring. The development of quantitative biomarkers and AI/ML integration could potentially lead to faster therapy effectiveness assessment, reducing the current months-long waiting period to days.
However, this is still in research phase with no clear timeline to commercialization or revenue generation. While the technology shows promise in improving cancer treatment monitoring, investors should note that research outcomes and regulatory approvals remain uncertain. The grant renewal, while positive for continued research funding, is unlikely to significantly impact QTI's
As reported in the past, the goal of the project is to develop an accurate, quantitative, portable, safe, and repeatable breast imaging approach for early identification of the response of breast cancer patients to neoadjuvant chemotherapy (NAC). As part of this grant, quantitative breast images with independent biomarkers known to be sensitive to cancer were to be collected, and the response of cancer to therapy was planned to be derived from quantitative ultrasound based on backscatter analysis.
The QTI Breast Acoustic CT™ System installed at Sunnybrook Health Sciences Center earlier in the year was used to collect high resolution breast images from female patients with independent biomarkers known to be sensitive to cancer. The backscatter analysis method was successfully tested on in vivo breast imaging data. As for the next steps, the team will incorporate the algorithms into the QTI image reconstruction flow through combined algorithms and apply AI/ML techniques to yield an improved estimate of NAC efficacy based on the quantitative biomarkers from QTI scans data and backscatter analysis. As these quantitative biomarkers were never before available with an imaging scan, they generate fertile ground for novel AI/ML development.
“We are very encouraged by the results of our study and are privileged to work with Michael Oelze, PhD at
About QT Imaging Holding, Inc.
QT Imaging Holdings, Inc. is a public (NASDAQ: QTI) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com.
Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding the grant goals and next steps. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the Breast Acoustic CT™ Scanner, the ability of QT Imaging Holdings to sell and deploy the Breast Acoustic CT™ Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holding’s (and its predecessor, GigCapital5, Inc.) filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241029323108/en/
For media inquiries, please contact:
Susan Schaffler
Head of Communications
Susan.Schaffler@qtimaging.com
Stas Budagov
Chief Financial Officer
Stas.Budagov@qtimaging.com
Source: QT Imaging Holdings, Inc.
FAQ
What is the purpose of QT Imaging's NIH-sponsored breast cancer study?
What institutions are collaborating with QT Imaging (QTI) on the breast cancer study?
How will QT Imaging (QTI) enhance their breast cancer imaging technology?
